ADMINISTRATION
1. The first dose of atezolizumab is infused over 60 minutes. If the initial dose is tolerated, subsequent doses may be infused over 30 minutes. 2. Do not administer as an intravenous push.
TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:// evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities but make, or consider, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. 
Drug name: Everolimus
Synonyms: RAD001, Afinitor
MECHANISM OF ACTION
Everolimus's inhibits the mammalian target of rapamycin (mTOR), a serine-threonine kinase. 9, 10 The mTor pathway plays a role in regulating cell proliferation and angiogenesis. The mTor pathway requires the cellular substrate p70 ribosomal S6 kinase 1 to be phosphorylated for proliferation. 10 Angiogenesis is promoted through the hypoxia-inducible factor-1 and growth factor protein translation. 10
PHARMACOKINETICS
Everolimus has a time to maximum plasma concentration (T max ) of 3 and 2 hours following a dose of 5 mg and 10 mg, respectively. Steady-state levels are reached after 8 days of treatment. 10 Everolimus is approximately 74% bound to serum proteins. Moderate hepatic impairment does not affect the degree of protein binding. The C max and minimum serum concentration (C min ) for a 5 mg dose are 37.9 ng/mL and 6.1 ng/mL, respectively. 11 For a 10 mg dose, the C max was 53.8 ng/mL and the C min was 14.5 ng/mL. 10 The clearance of drug from the blood (CL/F) was 15.8 L/h for the 5 mg dose and 16.99 L/h for the 10 mg dose. 10 Everolimus is metabolized primarily by cytochrome P450 3A4 isozyme. 12 The area under the blood concentration-time curve (AUC 0-t ) showed a range from 316-335 h•ng/mL and 588.6 h•ng/mL for the 10 mg dose. 10, 11 The volume of distribution (V d ) for everolimus is 1,613 L and halflife (t 1/2 ) is 35 hours. 12 Patients that consumed a high fat diet or a light fat diet had AUC reductions of 22% and 32%, respectively, compared to the fasting state. The C max was reduced by 54% and 42% with a high fat and light fat diet, respectively, compared to the fasting state. 13 Everolimus is excreted primarily in the feces (80%), with 5% being excreted in the urine. 13 Selected therapeutic regimens of everolimus appear in Table 2 .
PREPARATION

Follow institutional policies for preparation
of hazardous medications when dispensing everolimus. 2. Everolimus is available as 2.5, 5, 7.5, and 10 mg tablets and 2, 3, and 5 mg tablets for oral suspension. The manufacturer recommends against mixing the tablets and tablets for oral suspension together to achieve the desired dose. 3. The product's labeling recommends 13 : a. Not breaking or crushing tablets or oral suspension tablets. b. Using water as the only diluent for preparing everolimus suspension.
Note: PO = oral. a Conforms to dosing information listed in the manufacturer's labeling. 4. The product's labeling describes 2 procedures for preparing the oral suspension: a. Small glass:
(1) Place the oral suspension tablet in a small glass (maximum size 100 mL) and add approximately 25 mL of water. (2) Let the tablet sit in the water for 3 minutes.
(3) Gently stir the mixture and drink it. (4) Re-suspend any residue in the glass with another 25 mL of water and drink it. b. Oral syringe:
(1) Place the oral suspension tablet(s) in an oral syringe (at least 10 mL). (2) Draw 5 mL of water and 4 mL of air into the oral syringe and wait 3 minutes. (3) Gently invert the syringe at least 5 times to suspend the drug. (4) Draw an additional 5 mL of water into the syringe to re-suspend any residue, and drink it. 
STABILITY
TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http://evs. nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_ QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities but make, or consider, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%.
